Rapid Identification of Thrombocytopenia-Associated Multiple Organ Failure Using Red Blood Cell Parameters and a Volume/Hemoglobin Concentration Cytogram

Thrombocytopenia-associated multiple organ failure (TAMOF) has a high mortality rate when not treated, and early detection of TAMOF is very important diagnostically and therapeutically. We describe herein our experience of early detection of TAMOF, using an automated hematology analyzer. From 498,390 inpatients, we selected 12 patients suspected of having peripheral schistocytosis, based on the results of red blood cell (RBC) parameters and a volume/hemoglobin concentration (V/HC) cytogram. We promptly evaluated whether the individual patients had clinical manifestations and laboratory findings were consistent with TAMOF. Plasma exchanges were then performed for each patient. All 12 patients had TAMOF. The mean values of RBC parameters were significantly higher in all of the patients than with the reference range, however, 3 patients had % RBC fragments within the reference range. The mean value of ADAMTS-13 activity was slightly lower in patients compared with the reference range. Of the 12 patients, remission was obtained in 9 patients (75%) within 4 to 5 weeks using plasma exchanges. Three patients died. An increased percentage of microcytic hyperchromic cells with anisocytosis and anisochromia indicated the presence of schistocytes, making it an excellent screening marker for TAMOF. Identification of TAMOF with RBC parameters and a V/HC cytogram is a facile and rapid method along with an automated hematology analyzer already in use for routine complete blood cell counting test.

[1]  J. Carcillo,et al.  Plasma Therapies in Thrombotic Syndromes , 2005, The International journal of artificial organs.

[2]  Y. Abe,et al.  The Effectiveness of Measuring for Fragmented Red Cells Using an Automated Hematology Analyzer in Patients With Thrombotic Microangiopathy , 2009, Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis.

[3]  J. Vincent,et al.  The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure , 1996, Intensive Care Medicine.

[4]  J. Moake,et al.  Recent advances in thrombotic thrombocytopenic purpura. , 2004, Hematology. American Society of Hematology. Education Program.

[5]  J. Carcillo,et al.  Thrombocytopenia-associated Multiple Organ Failure: What Is It? Understanding Pathological Coagulation and Systemic Endotheliopathy Bench-to-bedside Review: Thrombocytopenia-associated Multiple Organ Failure – a Newly Appreciated Syndrome in the Critically Ill , 2022 .

[6]  M. Radhi,et al.  Thrombotic Microangiopathies , 2012, ISRN hematology.

[7]  J. Vincent,et al.  Serial evaluation of the SOFA score to predict outcome in critically ill patients. , 2001, JAMA.

[8]  L. Berggren,et al.  Plasma exchange as rescue therapy in multiple organ failure including acute renal failure. , 2003, Critical care medicine.

[9]  J. Carcillo,et al.  Is there a role for plasmapheresis/plasma exchange therapy in septic shock, MODS, and thrombocytopenia-associated multiple organ failure? We still do not know – but perhaps we are closer , 2002, Intensive Care Medicine.

[10]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[11]  R. Bick.  Disseminated Intravascular Coagulation: Pathophysiological Mechanisms and Manifestations , 1998, Seminars in thrombosis and hemostasis.

[12]  J. Kelton,et al.  Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura. Canadian Apheresis Study Group. , 1991, The New England journal of medicine.

[13]  C. Sprung,et al.  Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. , 1998, Critical care medicine.

[14]  J. Kelton,et al.  Comparison of Plasma Exchange With Plasma Infusion in the Treatment of Thrombotic Thrombocytopenia Purpura , 1992 .

[15]  T. Ohmori,et al.  Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure. , 2006, Blood.

[16]  F B Taylor,et al.  Towards Definition, Clinical and Laboratory Criteria, and a Scoring System for Disseminated Intravascular Coagulation , 2001, Thrombosis and Haemostasis.

[17]  B. Bain,et al.  Diagnosis from the blood smear. , 2005, The New England journal of medicine.

[18]  Martin Borggrefe,et al.  Use of soluble fibrin antigen instead of D-dimer as fibrin-related marker may enhance the prognostic power of the ISTH overt DIC score , 2004, Thrombosis and Haemostasis.

[19]  N. Puri,et al.  Thrombotic Thrombocytopenic Purpura Without Schistocytes on the Peripheral Blood Smear , 2005, Southern medical journal.

[20]  R. Bick.  Disseminated Intravascular Coagulation: Objective Clinical and Laboratory Diagnosis, Treatment, and Assessment of Therapeutic Response , 1996, Seminars in thrombosis and hemostasis.

[21]  Thomas Lecompte,et al.  Comparative evaluation of schistocyte counting by an automated method and by microscopic determination. , 2004, American journal of clinical pathology.